EXHIBIT 99.1

                                    PROXYMED
              Third Quarter 2002 Financial Results Conference Call
                                October 24, 2002
                                 10:00 a.m. EDT

Chairperson:  Michael K. Hoover, Chairman and Chief Executive Officer


Judd Schmid

       Thank you, Operator. Good morning everyone. Thank you for joining us for
ProxyMed's conference call to discuss the company's results for the third
quarter of 2002. I am Judd Schmid, ProxyMed's Chief Financial Officer. Before we
begin our discussion, let me take a minute to reference the Safe Harbor
statement under the Private Securities Litigation Reform Act of 1995. "This
conference call contains forward-looking statements that reflect the Company's
current assumptions and expectations regarding future events. While these
statements reflect the Company's current judgment, they are subject to risks and
uncertainties. Actual results may differ significantly from projected results
due to a number of factors, including, but not limited to the soundness of our
business strategies relative to the perceived market opportunities; our ability
to successfully identify and integrate acquisition candidates; our ability to
successfully develop, market, sell, cross-sell, install and upgrade our clinical
and financial transaction services and applications to current and new
physicians, payers, medical laboratories and pharmacies; our ability to
consummate and integrate any acquisitions successfully; our ability to compete
effectively on price and support services; our assessment of the healthcare
industry's need, desire and ability to become technology efficient; and our
ability and that of our business associates to comply with various government
rules regarding healthcare and patient privacy. These and other risk factors are
more fully discussed in the Risk Factor disclosure in our Form 10-K for the year
ended December 31, 2001 and our other filings with the Securities and Exchange
Commission, which we strongly urge you to read. ProxyMed expressly disclaims any
intent or obligation to update any forward-looking statements. When used, the
words "believes," "estimated," "expects," "anticipates," "may" and similar
expressions are intended to identify forward-looking statements."



       Leading today's conference call is Mike Hoover, ProxyMed's Chairman and
CEO, and providing an operational summary will be Nancy Ham, our President. Now
I would like to turn the call over to Mike.

Michael Hoover

       Good morning everyone, and welcome to ProxyMed's third quarter earnings
conference call. I am pleased to report that we had another quarter of improved
results on both an operational basis and at the bottom line. On a consolidated
basis we delivered revenue of $12.9 million and EBITDA of $1.1 million. This is
the first time in the company's history that we have exceeded the million-dollar
mark for EBITDA, and we also set a record for EBITDA margin at over 8%. This
positive result came primarily from our Transaction Services division getting
back on track with increased revenues, increased EBITDA and transaction growth
contributing to our success. In addition, Transaction Services had a
record-breaking quarter for signing new contracts, both at the physician and
partner level. We start the fourth quarter with a very large backlog - perhaps
the largest in our history - and with the new sales pipeline continuing to build
on this record success. We also completed two acquisitions in this division
during the quarter. In summary, we had a good quarter operationally, but perhaps
more importantly, we laid a lot of important groundwork that will pay off in the
fourth quarter. Some of these sales wins did come later, in fact much later,
than we had originally forecast, but they are in the door now and we are well
positioned to support our accelerating growth in Q4 and beyond.

       With no further delay, let me turn it over to Judd and Nancy to discuss
and review our third quarter results and the foundation for the fourth quarter.

Judd Schmid

       As Mike pointed out, we again had a successful quarter including the
reporting of EPS of $0.11, meeting our analysts' consensus. However, our results
included a favorable settlement of a contract dispute which added $265,000 to
net income, or $0.04 cents per share. As a result, we generated $0.07 per share
on an operational basis,

                                       2



an improvement over last quarter and a significant increase from the loss
reported in last year's third quarter.

       Turning now to our detailed results, ProxyMed is reporting quarterly
revenues of $12.9 million, (up 8% over the same period a year ago), EBITDA
profits of $1.1 million (an increase of 42% over that same quarter), and net
income of $724,000 or $0.11 per share (compared to a net loss of $4.3 million or
$1.85 loss per share last year). Our revenue increase came from our Healthcare
Transaction Services segment, where revenues increased 21% from $4.7 million
last year to $5.7 million this year. Included in these revenues is approximately
$323,000 of new revenues from our recent acquisitions of MDIP (in August) and
the customers acquired from Claimsnet.com (in mid-September).

       On a sequential basis, our overall revenue was up 2% over the second
quarter. Healthcare Transaction Services revenues led the way, increasing its
revenue by 8% on a sequential basis.

       The year-over-year revenue increase in Healthcare Transaction Services
was led by a 24% increase in total transactions processed over the third quarter
of 2001, as we processed a total of 29.2 million clinical and financial
transactions through ProxyNet, our secure, national healthcare information
network. Since transactions are a key driver of our business, we have increased
the amount of information provided in our earnings press release issued last
night. We hope this will provide more visibility to our analysts and to the
public. In today's market environment, more disclosure is certainly better.

       Let me take a minute to explain these new metrics we reported, and will
be reporting going forward. We have broken total transactions down into three
categories: "core" transactions (which include all transactions except for
encounters and transactions acquired in the current quarter), "acquired"
transactions (those from our current acquisitions), and "encounters". As we've
noted in the past, we are only able to report on acquisitions in the quarter
they happen since we pursue rapid integration, but we hope you will still find
the initial information useful.

       With regards to encounters, they are an administrative reporting
transaction for payers but do not generate revenue for the provider who must
submit them. Accordingly, rather than submitting on a daily or weekly basis,
most providers choose to periodically "catch up" on their submissions, and this
creates monthly and quarterly swings in both the number of encounters we
process, and what percentage of our transaction mix they represent. Since
encounters are at a significantly lower price point than claims, these swings
make it difficult to easily analyze our

                                        3



quarter-over-quarter growth in our core business. In addition, we do not expect
our encounter volume to grow on an annual basis, as payers are not expanding the
capitated service model underpinning encounters. Therefore, we believe that
breaking out encounters will show more clearly our growth in core transactions,
which are the growth engine for Transaction Services.

         As you saw in the press release, included in the current quarter's
total transactions of 29.2 million transactions are 22 million core
transactions, 6 million encounters and 1.2 million acquired financial
transactions. "Peeling the onion" then, our core transaction growth is up 32%
from last year. Sequentially, core transactions are up 4% since last quarter.
And just to clarify, since we get many questions on internal growth vs. growth
from acquisitions, our overall transaction increase was 5.6 million total
transaction, or 24%, from Q3 2001 to Q3 2002. Of this increase, only 1.2
million, or 22%, was related to acquisitions, while 4.4 million, or 78%, was due
to internal growth. As a result, we are currently on an annualized run rate of
almost 119 million total transactions.

         On the expense side, as we continue to monitor and control our SG&A
expenses, we were able to decrease our consolidated SG&A expenses by $50,000,
even after additional expenses from our acquisitions. As a percentage of
revenues our SG&A expenses dropped from 47.1% to 45.8% from last quarter.

         EBITDA dollars continued to increase and we reported an EBITDA profit
of $1,068,000 for the quarter, an increase of 42% from last year's EBITDA of
$754,000, and a 19% increase over last quarter's EBITDA of $901,000. We remain
confident in achieving expanding EBITDA margins on an annual basis and our
consolidated EBITDA margin for the quarter was 8.3%, up from 7.1% last quarter.

         With our allocation of purchase prices completed, amortization expense
related to our 2002 acquisitions of KenCom, MDIP and Claimsnet.com totaled
$140,000 for the quarter and is expected to run approximately $146,000 per
quarter going forward.

         Also below the EBITDA line, as noted previously, we favorably settled a
contract dispute in our Lab Communications business unit, for $265,000, net of
legal expenses.

         As a result of the above, net income for the third quarter increased to
$724,000 from a loss of $4.3 million last year and net income of $446,000 last
quarter.

         Just a couple of comments now on the balance sheet and capital
structure. We continue to be in a great financial position, with cash of $24
million, strong working capital led by our

                                       4



Accounts Receivable DSO of 42 days and no debt. We've also lowered our inventory
levels as we've improved our ordering methodologies. During the quarter, we
spent $533,000 in capital expenditures primarily for upgrades and enhancements
to our customer relationship software, for HIPAA compliance, and for our data
center consolidation efforts. We also added to the balance sheet $76,000 in
capitalized software development related to our production network enhancements
and other projects. We will continue to capitalize appropriate development
expenses and expect the rate of capitalization to increase slightly for the
balance of the year. As a result, our consolidated capitalized software
development is expected to be between 14% and 17% of our total research and
development costs for all of 2002, up slightly from our last quarter's estimate
of 10% to 15%.

         Our capital structure remains virtually unchanged from last quarter.
Our Compensation Committee did approve the issuance of 138,500 options across
the company during the quarter, including 103,000 options to executive
management. As a result, our current capital structure, is as follows: 6,742,000
million shares outstanding; 20,000 underlying common shares for our preferred
stock; 730,000 warrants; and 1,070,000 stock options all totaling 8.6 million
fully-diluted shares.

Nancy Ham:

         So far in this call we have talked mainly about our third quarter
results. We were able to meet our bottom line EPS consensus of $0.11, but as
Judd discussed, we were behind at the operating line. I'm going to focus now on
what happened in third quarter that contributed to this, but perhaps more
importantly, I'm going to walk through some of our outlook for the fourth
quarter in some detail so that we give you maximum visibility into the sources
of increased transactions, revenue and EBITDA.

         Let's start by discussing Transaction Services, which includes our
payer services and prescription services divisions, and our performance in Q3.
On the physician side of our network, we added 2,900 physicians during the
quarter, handily beating our previous quarterly total of 1,815. These new
physicians signed up for over 6,400 services, or 2.2 services per physician. I
would like to congratulate the entire sales team on a terrific job! Our

                                       5




implementation team is now hard at work converting those physicians into revenue
producers for Q4 and beyond.

         In addition to this direct customer expansion, we added 17 new
Electronic Commerce Partners, representing almost 9,500 indirect physicians in
multiple markets and bringing our total of active partners to 175. We ended the
quarter with direct relationships with over 70,000 physicians and indirect
relationships with another 56,000.

         Turning now to payers, in addition to Aetna, we signed up another 4 new
payers in the quarter. Combined with payers from our MDIP acquisition, this
brings our total of direct payer connections to 394. Although we have been very
successful at signing new payers, for the next 12 months or so, we will be
shifting our payer sales focus. Most payers are now very internally focused with
their HIPAA compliance efforts, and as a result we do not anticipate a lot of
new payer connections being granted in the industry. In contrast, we see payers
making the decision to actually REDUCE their overall numbers of connections to
concentrate their connectivity with fewer, higher quality partners who can
deliver HIPAA compliance. We think this is a tremendous opportunity for
ProxyMed. Today we generally only have a physician claims and encounter
connection with our payers. Therefore we are focusing our sales efforts over the
next few quarters on cross-selling our existing 394 payers to add hospital and
dental claims, real-time transactions and our FOCUS program for converting small
physician offices from submitting on paper to submitting electronically. With
our strong existing payer relationships, and with our Aetna implementation as a
benchmark reference, we think this payer cross-sell opportunity will be
significant for us.

         Since Judd has already discussed the financial results for the third
quarter, I'd like to focus on the important building blocks we accomplished in
the quarter, and how that translates into improved results for the fourth
quarter. One of the biggest accomplishments of course was signing the Aetna
contract. As you will recall, we signed a national contract with Aetna on July
1st for a complete suite of physician and hospital transactions. I am very
pleased to report that Aetna has been in production for physician claims since
October 7th, and for hospital claims since October 11th. In addition to this
success on the implementation side, we are also doing very well on the sales
front. In the initial press release, we stated that in the first year of the
agreement we anticipated sending Aetna over 7 million electronic transactions. I
am pleased to report that we are already on track to exceed that number, which I
will explain in detail.

                                       6



     Having Aetna in production on a direct basis drives several major
improvements to our transaction volume and financials. First, ProxyMed has been
sending approximately 250,000 claims per month to Aetna through another
connection. Under our new contract, we have moved of course to a direct
connection, which carries significantly better reimbursement rates. Second, we
have already signed contracts with other partners totaling over 350,000 Aetna
claims per month, with additional contracts in various final stages of
negotiations. The currently contracted partners will have the majority of their
volume migrated to us during this month, with additional volume from them and
from the remaining contracts coming on board in November and December. Finally,
the addition of the remaining Aetna transactions (eligibility, referrals, claims
status and ERA) over the rest of the quarter will also drive additional growth.
We estimate that the net effect of Aetna will drive additional EBITDA in the
fourth quarter of between $85,000 (based on what is already contracted) and
$150,000 (based on our total pipeline).

     In addition to Aetna, we had a very successful third quarter for new
business. Along with our record setting 2,900 new physicians, we also signed a
number of contracts with larger billing services, physician groups and strategic
partners. On the 12 largest contracts, we did experience a significant delay in
the legal contracting cycle as everyone struggled with how to handle HIPAA
liability for the first time. In fact, on average these contracts closed more
than 90 days later than originally planned, which means they did not have a
chance to impact the third quarter. However, they are in the door now, and
represent over 1.0 million transactions on a monthly basis at full ramp.

     In addition to these contracting delays, I have to admit that over the past
quarter we also had a bit of a bottleneck in implementation due to our dedicated
focus on the Aetna implementation for most of August and especially September.
However, with Aetna now in production, implementation is back to its normal
schedule, and we should add at least $90,000 to $110,000 in EBITDA in Q4 from
these signed contracts.

     On the acquisition side, in the fourth quarter we will have three full
months of MDIP (vs. two months in the third quarter), and three full months of
Claimsnet (vs. a partial month in the third quarter). This will add
approximately $85,000 to 100,000 in incremental EBITDA.

     Finally, Q4 is traditionally a strong quarter for encounters and for
overall claims submission as providers seek to close out the fiscal year with
all filings up to date

                                       7



     Shifting now to Prescription Services, the big news during the quarter was
the signing of our national connectivity agreement with Rite Aid. One of the
nation's largest pharmacy chains with over 3,500 stores, Rite Aid adds
significant presence in a number of new markets, such as San Francisco, where
ProxyMed already has a large base of customers for our financial products, and
Michigan. We anticipate that Rite Aid will be in production by the end of
November, although it will not add a significant amount of revenue in the fourth
quarter. The bigger source of Q4 growth will instead be from our just announced
relationship with SureScript, which provides for financial sponsorship of the
first year's subscription fee for up to 3,000 physicians. This sponsorship
should allow us to greatly accelerate the signing of new physicians, and in
fact, we have already signed up over 100 new physicians in the first few weeks,
with some very large groups in the pipeline.

     Turning now to Lab Communication Solutions, we had a solid quarter on the
technology and services side. We continue to make steady progress in enrolling
customers in our subscription-based FleetWatch service, with another 330
physician offices enrolled during the quarter. This brings our total sales to
over 1,500 offices since January of this year. In addition, for the past three
years we have been providing services to half of Quest Diagnostics (the former
SmithKline Beecham business) under a subcontract with another party. That
subcontract has expired and we are now providing our services on a direct basis
to all of Quest Diagnostics. We hope that this will allow us to forge a closer
service and support relationship with this important customer, who is the
largest lab in our industry, and getting larger through acquisitions.

     In fact, let me take a minute to talk about the changing dynamics in our
lab customer base. When we began the year, our top 6 customers, in alphabetical
order, were Ameripath, AML, Dynacare, LabCorp, Quest Diagnostics, and Unilab.
Assuming that the pending acquisition of Unilab by Quest closes, then we will
have seen our top 6 customers combine to become our top three. As you can
imagine, all this activity has caused various delays and disruptions in normal
ordering patterns for our products. The LabCorp-Dynacare merger in particular
slowed business this year, as we assisted LabCorp in converting the Dynacare
fleet rather than forcing the sales of replacement reporting devices. While this
hurt us in the short run, this cooperation has been much appreciated by LabCorp
and has solidified our relationship. In addition, we're starting to realize new
gains in product business with Quest. Quest, Unilab and AML business, on a
consolidated basis, has increased 62% year to date, and in Q3 was up over

                                       8



108% to Q3 last year. So as you can see, the disruptions caused by these mergers
is gradually resolving itself, with Key retaining our position as the sole or
largest supplier to both Quest and LabCorp.

     Primarily as a result of these merger-related disruption, revenues and
EBITDA were basically flat to slightly down over both the prior quarter and over
the same period last year.

     Looking ahead to the fourth quarter, this is historically a difficult
quarter due to the exhaustion of capital budgets at our customers. However, we
believe that the turnaround in device orders from Quest Diagnostics will
continue as we fulfill orders for pent-up demand created by these
consolidations. In addition, this quarter we are completing the first phase
rollout of a new color results reporting device for a leading anatomic pathology
laboratory. Based on the initial success to date, we anticipate that this
offering will be rolled out to the remaining regions beginning late this year
and on into the first quarter of 2003. We have also been working hard to build
the services and contract manufacturing business, as I was just discussing,
which helps to mitigate these historical quarterly swings in product orders. It
is rather early still in the quarter, but the initial signs are promising that
revenue will be steady compared to the third quarter and will not suffer the
typical drop-off.

Michael Hoover:

     I admit that I am somewhat challenged to summarize the quarter. Overall, I
am very pleased with the performance of our team, especially as we look back at
where we have come from. We find ways to meet our goals, such as our EPS
consensus guidance for the quarter. However, we can't avoid the fact that
although we did meet our EPS consensus, we fell short on the operating line. I
absolutely do not believe that this shortfall reflects any weakness in our
business model or our market position, and I'd like to take a minute to discuss
this.

     Our company has made tremendous progress over the past 4 short quarters.
Revenue is up over 20% from the prior period. EBITDA has gone from a
long-standing negative number to breaking the $1 million dollar mark for the
first time. We have delivered 2 consecutive quarters of positive and increasing
EPS. Our balance sheet and capital structure have gone from a

                                       9



complex mess to a debt free balance sheet with $24 million in cash. Financially,
we are in the best shape ever.

     Our operational metrics are equally strong. Our transaction run rate has
increased from 94 million to over 119 million. We have signed up an additional
10,000 doctors, growing our direct physician customer base from 60,000 to
70,000. And our payer connectivity has exploded from 333 to almost 400.

     In addition to signing up all these new physicians, we have been able to
sell more services to our existing customers. Over the past year we've grown our
services per physician from 1.3 to 2.05, proving that our cross-selling model
works. In addition, we've been able to make some small but smart acquisitions.
We've made these acquisitions with cash, causing no dilution to our
shareholders, and we've been able to integrate them quickly. All this proves to
me that our focused business model is working, and that it is sustainable over
the next three to five years.

     Looking ahead, we have a lot of new business already in hand that is coming
on stream in the fourth quarter. Taking our Q3 exit rate and adding the specific
items Nancy discussed, which included our new direct connection to Aetna and
pull-through of our large backlog, we already have clear visibility for $13
million in revenues and $1.3 million in EBITDA for Q4, with identified
opportunities totaling up to another $ 1 million in revenue and $600,000 in
EBITDA, for a potential total of $14 million in revenue and $1.9 million in
EBITDA. This translates into an EPS range of $0.09 to $0.17 per share. We
certainly have a lot of work to do to meet the high end of our range, but the
team is 100% focused on what needs to happen.

     With regards to our outlook for 2003, we will have our budgets complete by
late November and will provide an update at that time.

     We remain confident of our ability to grow revenue on an annual basis at
20-30 percent, and to grow EBITDA and EPS at 50 to 100 percent.

                          [END OF INFORMATION PROVIDED]

                                       10